COMPUGEN LTD (CGEN)
IL0010852080 - Common Stock
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Participate in Stifel 2024 Healthcare Conference
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Present New Clinical Data at SITC 2024
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Present at Single Cell Genomics 2024 Conference
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
CGEN Stock Earnings: Compugen Beats EPS, Beats Revenue for Q2 2024
CGEN stock results show that Compugen beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Compugen Reports Second Quarter 2024 Results
FDA clearance of COM503 IND in July 2024 triggered a $30 million milestone payment from Gilead On track to present data from COM701 + COM902 + pembrolizumab,...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Present at Upcoming Antibody Industrial Symposium
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
CGEN Stock Earnings: Compugen Misses EPS, Misses Revenue for Q1 2024
CGEN stock results show that Compugen missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Compugen Reports First Quarter 2024 Results
Enrollment completed and on track to present data from COM701 + COM902 + pembrolizumab platinum resistant ovarian cancer study in Q4 2024 Data from COM701 +...
Compugen Appoints David Silberman as Chief Financial Officer
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Participate in Two Upcoming Investor Conferences
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
CGEN Stock Earnings: Compugen Misses EPS, Beats Revenue for Q4 2023
CGEN stock results show that Compugen missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
CGEN Stock Earnings: Compugen Misses EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Compugen (NASDAQ:CGEN) just reported results for the fourth quarter of 2023.Com...
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
7 Speculative Stocks to Double Your Money THIS Year
Although terribly risky, these stocks to double your money could be enticing if you have some pocket change lying around.
Compugen regains compliance with Nasdaq's minimum bid price requirement (NASDAQ:CGEN)
Compugen regains compliance with Nasdaq's minimum bid price requirement after receiving a non-compliance notice for failing to maintain $1.00 share price.
Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery,...
Compugen stock rockets 160% on Gilead development deal (NASDAQ:CGEN)
Compugen (CGEN) shares rocketed 160% in morning trading Tuesday after the Israeli drug developer announced a development deal with Gilead Sciences (GILD) worth
Why Are Stocks Up Today?
Stocks are up today and investors wondering why will want to keep reading as we have a breakdown of the market's rally on Tuesday!
Why Is Compugen (CGEN) Stock Up 189% Today?
Compugen stock is up on Tuesday as investors in CGEN shares react to an exclusive licensing agreement with Gilead Sciences.